HBK Sorce Advisory’s Adaptimmune Therapeutics ADAP Stock Holding History

HBK Sorce Advisory’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-70,000	Closed	-$65K	–	590
2022 Q4	$65K	Buy	70,000 +35,000	+100%	+$56.7K	﹤0.01%	709
2022 Q3	$32K	Buy	+35,000	New	+$64.3K	﹤0.01%	533

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

HBK Sorce Advisory's ADAP Position: Q1 2023 in Review

HBK Sorce Advisory sold out of Adaptimmune Therapeutics (ADAP) in Q1 2023, closing a stake of 70,000 shares — an estimated $65K sold.

HBK Sorce Advisory first reported a position in ADAP in Q3 2022 and held it in 2 quarters. The position peaked at $65K in Q4 2022. 65 funds tracked by Wall St. Rank hold ADAP as of Q1 2023.

HBK Sorce Advisory reported no remaining Adaptimmune Therapeutics position as of Q1 2023 after selling out during the quarter.
HBK Sorce Advisory sold 70,000 Adaptimmune Therapeutics shares in Q1 2023, an estimated $65K.
HBK Sorce Advisory first reported a position in Adaptimmune Therapeutics in Q3 2022 and held it in 2 quarters.
HBK Sorce Advisory's Adaptimmune Therapeutics position peaked at $65K in Q4 2022.
65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.